How Will The Metastatic Lung Adenocarcinoma Treatment Market Expand At A CAGR Of 9.8% Through 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Big Is The Metastatic Lung Adenocarcinoma Treatment Market Today And What Is Its Future Size?
In recent times, the market size for metastatic lung adenocarcinoma treatment has shown significant growth. Projected to surge from $4.13 billion in 2024 to $4.54 billion in 2025, it is set to experience a compound annual growth rate (CAGR) of 10.0%. Factors contributing to this historic growth include the rising occurrence of lung cancer, increased demand for targeted therapies, a surge in acceptance of immunotherapy, amplified investments in cancer research, as well as heightened awareness about early detection and diagnosis.
In the coming years, a significant increase is expected in the market size for the treatment of metastatic lung adenocarcinoma. The market is projected to augment to $6.59 billion by 2029, with a compound annual growth rate (CAGR) of 9.8%. This growth in the projected timeline can be linked to factors such as the escalating rates of smoking and environmental influences, the increased sanctioning of innovative drug therapies, enhancements in healthcare infrastructure in developing markets, the surge in personalized medicine, and heightened collaborations between pharmaceutical firms and research bodies. The forecast period also showcases notable trends like the progress in liquid biopsy technologies, enhanced combo therapies for improved results, breakthroughs in targeted drug delivery systems, the growth in AI-powered diagnostics for precision treatment, and the development in immuno-oncology treatments.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24320&type=smp
What External And Internal Drivers Are Influencing The Metastatic Lung Adenocarcinoma Treatment Market?
The rise in the use of targeted therapy is anticipated to fuel the advancement of the metastatic lung adenocarcinoma treatment market in the future. This specific cancer treatment utilizes drugs that accurately obstruct cancer expansion by focusing on certain genes or proteins aiding in tumor progression and distribution. Targeted therapy is gaining popularity as it precisely handles specific genetic mutations, which implies more successful treatment results and lesser side-effects in comparison to traditional methods. Utilized in treating metastatic lung adenocarcinoma, targeted therapy interrupts particular genetic mutations that promote cancerous growth and distribution. This therapy, with its precision and less side effects, considerably improves survival rates and the quality of life in patients with actionable mutations. For example, in July 2023, as reported by the American Society of Gene and Cell Therapy (ASGCT), a professional membership organization from the US, and Citeline, a US-based supplier of drugs and devices, the count of gene therapies in Phase II had reached 247 by the end of Q1 2023, and rose by 5% to 260 by the end of Q2. Therefore, the growing deployment of targeted therapy is steering the growth of the metastatic lung adenocarcinoma treatment market.
How Is The Metastatic Lung Adenocarcinoma Treatment Market Categorized Across Applications And Types?
The metastatic lung adenocarcinoma treatmentmarket covered in this report is segmented –
1) By Treatment: Chemotherapy; Targeted Therapy; Immunotherapy; Radiation Therapy
2) By Route of Administration: Oral; Intravenous
3) By End-User: Hospitals; Cancer Research Centers; Specialty Clinics
Subsegments:
1) By Chemotherapy Drugs: Platinum-Based Chemotherapy; Non-Platinum Chemotherapy; Combination Therapy; Single-Agent Chemotherapy
2) By Targeted Therapy,: Epidermal Growth Factor Receptor Inhibitors; Anaplastic Lymphoma Kinase Inhibitors; C-Ros Oncogene 1 Receptor Tyrosine Kinase Inhibitors; V-Raf Murine Sarcoma Viral Oncogene Homolog B1 Inhibitors; Rearranged During Transfection Inhibitors; Mesenchymal-Epithelial Transition Factor Inhibitors; Neurotrophic Tropomyosin Receptor Kinase Inhibitors
3) By Immunotherapy: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors; Combination Immunotherapy; CAR-T Cell Therapy (Emerging)
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Stereotactic Body Radiotherapy (SBRT); Intensity-Modulated Radiation Therapy (IMRT); Proton Therapy
Which Emerging Trends Are Reshaping The Metastatic Lung Adenocarcinoma Treatment Market Landscape?
In the metastatic lung adenocarcinoma treatment market, leading companies are prioritizing the development of sophisticated solutions such as treatments devoid of chemotherapy. These solutions aim to boost long-term survival rates by specifically targeting genetic mutations, thus enhancing patient outcomes. Chemotherapy-free treatment involves cancer management approaches such as targeted therapy or immunotherapy, which are intended to control cancer more effectively while minimizing the harsh side effects often associated with conventional chemotherapy. Case in point, in August 2024, Johnson & Johnson, an American healthcare corporation, revealed that the U.S. Food and Drug Administration (FDA) had granted approval for RYBREVANT (amivantamab-vmjw) in coordination with LAZCLUZE (lazertinib) as the introductory, chemotherapy-free treatment for adults diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) exhibiting EGFR exon 19 deletions or exon 21 L858R substitution mutations. The approval was reinforced by the results from the Phase 3 MARIPOSA study, which showed a superior progression-free survival relative to osimertinib.
Who Are The Global Leaders Steering The Metastatic Lung Adenocarcinoma Treatment Market Forward?
Major companies operating in the metastatic lung adenocarcinoma treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Exelixis, BeiGene Ltd., Novocure, Blueprint Medicines Corporation.
Access The Complete Report Here:
What Are The Emerging Regional Trends Driving The Metastatic Lung Adenocarcinoma Treatment Market?
North America was the largest region in the metastatic lung adenocarcinoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic lung adenocarcinoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=24320&type=smp
Browse Through More Reports Similar to the Global Metastatic Lung Adenocarcinoma Treatment Market 2025, By The Business Research Company
Lung Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report
Lung Cancer Diagnostic And Screening Global Market Report 2025
Small Cell Lung Cancer Therapeutics Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
